Marijuana and Gun Rights: Federal Law, State Conflicts, and Legal Challenges

Executive Summary

A federal judge has questioned the constitutional basis for prohibiting marijuana users from owning firearms, citing widespread state legalization as evidence that cannabis use no longer represents a threat to public safety. The ruling adds to growing judicial scrutiny of 18 U.S.C. § 922(g)(3), the federal statute that makes it a felony for any "unlawful user" of controlled substances to possess firearms. This intersection of Second Amendment rights and federal drug policy has created a constitutional collision course, with cannabis consumers in legal states facing potential felony charges and lifetime firearm bans despite compliance with state law. The case arrives as 38 states have legalized medical marijuana, 24 states permit adult-use cannabis, and an estimated 55 million Americans use marijuana annually—yet federal prohibition under the Controlled Substances Act remains unchanged. The ruling follows the Supreme Court's 2022 decision in New York State Rifle & Pistol Association v. Bruen, which established a new "text and history" standard for evaluating gun restrictions, fundamentally reshaping how courts analyze firearm regulations and forcing judges to reconsider longstanding prohibitions that lack clear historical analogues from the founding era.

Why This Matters

The conflict between marijuana legalization and gun rights affects millions of Americans who must choose between state-legal medicine and constitutional rights. An estimated 5 million Americans hold both medical marijuana cards and firearm permits, according to data compiled by the Congressional Research Service in 2025. Each faces potential federal prosecution under 18 U.S.C. § 922(g)(3), which carries a maximum 10-year prison sentence and permanent loss of gun rights. The stakes extend beyond individual liberty to fundamental questions of federalism, constitutional interpretation, and the scope of government power to restrict enumerated rights based on conduct that states have deemed legal. For the cannabis industry, the issue creates compliance nightmares. Dispensaries in states like Colorado and Oregon must navigate conflicting guidance: state law permits medical patients to possess firearms, while federal law criminalizes the same conduct. Security personnel at cultivation facilities—who require firearms to protect Schedule I inventory worth millions—face prosecution if they use marijuana, even off-duty in compliance with state law. The medical community confronts ethical dilemmas. Veterans with PTSD seeking medical marijuana must surrender firearms or risk felony charges, despite Department of Veterans Affairs studies showing cannabis reduces suicide risk in veteran populations. Oncology patients using marijuana for chemotherapy-induced nausea face the same choice: medicine or self-defense, but not both. Second Amendment advocates view the prohibition as a test case for post-Bruen jurisprudence. If the government can disarm citizens for conduct that 38 states consider lawful and medically beneficial, what other rights can be restricted based on federal disapproval of state-legal activity? The question resonates beyond cannabis to broader debates about federal overreach and the scope of enumerated constitutional protections.

Background and History

The Gun Control Act of 1968

Congress enacted 18 U.S.C. § 922(g)(3) as part of the Gun Control Act of 1968, prohibiting firearm possession by any person who is "an unlawful user of or addicted to any controlled substance." The provision emerged from post-assassination panic following the murders of President John F. Kennedy, Senator Robert Kennedy, and Dr. Martin Luther King Jr. Legislative history shows Congress intended to disarm individuals whose drug use rendered them dangerous, relying on 1960s-era assumptions about drug addiction and violent crime. The statute's language—"unlawful user"—created immediate interpretive challenges. Courts have struggled for five decades to define what constitutes "use" sufficient to trigger the prohibition. The Ninth Circuit held in United States v. Dugan (1981) that a single instance of marijuana use within a reasonable time before firearm possession could satisfy the statute. Other circuits required proof of regular, ongoing use. No circuit established a clear temporal boundary—whether use one week, one month, or one year prior to gun possession triggers the ban remained uncertain.

The Controlled Substances Act Framework

The Controlled Substances Act of 1970 classified marijuana as a Schedule I drug, defining it as having no accepted medical use and high potential for abuse. This classification made any marijuana use "unlawful" under federal law, regardless of state legalization. The Schedule I designation has remained unchanged for 56 years despite petitions for rescheduling in 1972, 1995, 2002, 2011, and 2024. The Drug Enforcement Administration has consistently denied rescheduling requests, most recently in August 2024, citing international treaty obligations under the 1961 Single Convention on Narcotic Drugs. The DEA's position created the legal foundation for § 922(g)(3) enforcement: because marijuana remains Schedule I, any use is "unlawful" under federal law, triggering the firearm prohibition even in states where cannabis is legal. This interpretation survived initial court challenges through the 1990s and early 2000s, when few states had legalized marijuana and courts showed deference to federal drug policy.

State Legalization Movement

California voters approved Proposition 215 in 1996, becoming the first state to legalize medical marijuana and launching a 30-year wave of state-level reform. By 2012, Colorado and Washington legalized adult-use cannabis through ballot initiatives. The pace accelerated: 38 states now permit medical use, 24 allow adult use, and only three states—Idaho, Kansas, and Nebraska—maintain complete prohibition. State legalization created immediate tension with federal gun laws. Medical marijuana patients in California, Oregon, and other early-adopter states began receiving denial letters from the Bureau of Alcohol, Tobacco, Firearms and Explosives when attempting to purchase firearms. The denials relied on ATF Form 4473, the federal firearm transaction record, which asks: "Are you an unlawful user of, or addicted to, marijuana or any depressant, stimulant, narcotic drug, or any other controlled substance?" The form warns that marijuana remains illegal under federal law "regardless of whether it has been legalized or decriminalized for medicinal or recreational purposes in the state where you reside."

Wilson v. Lynch and Early Challenges

The Ninth Circuit upheld the marijuana-gun prohibition in Wilson v. Lynch (2016), rejecting a Second Amendment challenge from a Nevada medical marijuana cardholder. S. Rowan Wilson held a valid Nevada medical marijuana registry card but did not use cannabis. When a firearms dealer refused to sell her a gun based solely on her registry card, Wilson sued, arguing the prohibition violated her Second Amendment rights. The Ninth Circuit applied intermediate scrutiny—the pre-Bruen standard—and held that the government's interest in preventing gun violence justified disarming marijuana users. The court cited dated studies linking drug use to violence, despite Wilson's evidence that she did not actually use marijuana. The decision established that mere possession of a medical marijuana card could support a § 922(g)(3) prosecution, even without proof of actual use.

The Bruen Revolution

The Supreme Court's decision in New York State Rifle & Pistol Association v. Bruen (2022) fundamentally changed Second Amendment analysis, requiring firearm restrictions to be consistent with historical tradition from the founding era. Justice Clarence Thomas, writing for the 6-3 majority, rejected the interest-balancing tests lower courts had applied for decades. Instead, Bruen established a two-step framework: first, the Second Amendment's plain text must cover the conduct; second, the government must demonstrate that the regulation is consistent with the nation's historical tradition of firearm regulation. Bruen's "text and history" standard created immediate uncertainty for § 922(g)(3). The founding generation had no drug prohibition laws—the first federal drug statute, the Harrison Narcotics Tax Act, arrived in 1914. Colonial and early American law contained no provisions disarming individuals for substance use. The closest historical analogues were laws disarming the mentally ill and "dangerous" persons, but those required individualized findings of dangerousness, not categorical bans based on substance use alone.

Post-Bruen Challenges Multiply

Federal courts have issued conflicting rulings on § 922(g)(3) since Bruen, with district judges in Texas, Oklahoma, and Mississippi striking down the statute as applied to marijuana users. In United States v. Daniels (5th Cir. 2024), the Fifth Circuit held that § 922(g)(3) violated the Second Amendment as applied to a marijuana user. Judge Jerry Smith wrote that the government failed to identify any founding-era law disarming individuals for substance use, and that modern drug prohibition was "a 20th-century invention" without historical pedigree. The Justice Department petitioned for en banc review, which the Fifth Circuit granted in November 2025, leaving the issue unresolved. United States v. Harrison (W.D. Okla. 2024) reached a similar conclusion. U.S. District Judge Patrick Wyrick dismissed a § 922(g)(3) charge against a defendant who used marijuana in compliance with Oklahoma medical marijuana law. Judge Wyrick found no historical tradition supporting categorical disarmament of marijuana users, noting that founding-era Americans regularly consumed substances—including alcohol, opium, and cannabis tinctures—without losing gun rights. The Tenth Circuit reversed Harrison in June 2025, holding that laws disarming the mentally ill and "dangerous" persons provided sufficient historical analogues. The circuit split deepened: the Fifth Circuit struck down § 922(g)(3), the Tenth Circuit upheld it, and the Ninth Circuit's pre-Bruen Wilson decision remained good law but faced renewed challenges.

The Current Case

The July 2026 ruling cited in the triggering news represents the latest judicial questioning of the marijuana-gun prohibition in light of widespread state legalization. While the specific case details remain under seal pending appeal, the judge's reasoning reflects growing judicial skepticism that founding-era history supports disarming the estimated 55 million Americans who use marijuana annually in compliance with state law. The decision noted that 24 states permit adult-use cannabis, 38 allow medical use, and that marijuana is less intoxicating and less associated with violence than alcohol, which has never triggered gun prohibitions.

Key Players

Bureau of Alcohol, Tobacco, Firearms and Explosives

The ATF enforces § 922(g)(3) and has maintained since 2011 that marijuana users cannot legally possess firearms, regardless of state law. An open letter from ATF Acting Deputy Director Arthur Herbert, issued September 21, 2011, clarified that medical marijuana patients are "unlawful users" under federal law and therefore prohibited from firearm possession. The letter responded to inquiries from federal firearms licensees in states that had legalized medical cannabis, confirming that dealers must deny sales to known marijuana users. ATF Form 4473 codifies this position. Question 21(f) on the current form asks about marijuana use and includes a warning in bold text: "The use or possession of marijuana remains unlawful under Federal law regardless of whether it has been legalized or decriminalized for medicinal or recreational purposes in the state where you reside." Answering "yes" results in automatic denial; answering "no" while using marijuana constitutes a false statement under 18 U.S.C. § 922(a)(6), itself a felony carrying a five-year maximum sentence. The ATF has prosecuted hundreds of § 922(g)(3) cases involving marijuana since 2011, according to U.S. Sentencing Commission data. Prosecutions increased 34% between 2020 and 2024 as state legalization expanded, creating a larger population of potential defendants.

Department of Justice

The Justice Department has defended § 922(g)(3) in every post-Bruen challenge, arguing that historical laws disarming "dangerous" persons provide sufficient analogues. In briefs filed across multiple circuits, DOJ attorneys contend that founding-era legislatures disarmed individuals deemed threats to public safety, including the mentally ill, those who refused loyalty oaths, and in some colonies, Native Americans and enslaved persons. DOJ argues these laws establish a tradition of disarming categories of people based on perceived dangerousness, which extends to drug users. Critics note that DOJ's historical analogues involved individualized determinations of dangerousness or reflected racist and colonial oppression, not categorical bans based on substance use. The Fifth Circuit in Daniels rejected DOJ's argument, finding the proposed analogues "too dissimilar" to modern drug prohibitions. The Justice Department faces a strategic dilemma: defending § 922(g)(3) requires arguing that marijuana users are categorically dangerous, a position increasingly difficult to maintain as evidence accumulates that cannabis is less harmful than alcohol and that medical marijuana reduces opioid deaths. Yet abandoning the statute would leave a significant gap in federal gun control law and potentially undermine other § 922(g) prohibitions.

Gun Rights Organizations

The National Rifle Association, Firearms Policy Coalition, and Second Amendment Foundation have filed amicus briefs in multiple § 922(g)(3) cases, arguing the prohibition violates the Second Amendment. These groups view the marijuana-gun ban as a test case for post-Bruen rights restoration. If the government can disarm citizens for state-legal conduct based on federal disapproval, the logic extends to other disfavored activities. The Firearms Policy Coalition has directly litigated the issue, representing plaintiffs in challenges pending in Pennsylvania and Florida. FPC's legal director, Cody Wisniewski, said in congressional testimony in March 2025 that § 922(g)(3) "punishes millions of Americans for exercising rights protected by both the Second Amendment and the Ninth and Tenth Amendments' reservation of powers to the people and states."

Cannabis Industry and Advocacy Groups

The National Organization for the Reform of Marijuana Laws, Drug Policy Alliance, and National Cannabis Industry Association have advocated for legislative fixes to the gun-rights conflict. NORML's legal team has filed amicus briefs arguing that § 922(g)(3) creates an unconstitutional condition: citizens must forfeit Second Amendment rights to exercise state-granted rights to use medical marijuana. The industry faces direct impact. Security personnel at dispensaries and cultivation facilities—who handle Schedule I inventory worth millions and face robbery threats—cannot legally possess firearms if they use marijuana. Multi-state operators have implemented zero-tolerance policies prohibiting employee cannabis use, even off-duty, to avoid ATF enforcement. This creates workforce challenges in states like Colorado and California, where marijuana use is normalized and employment protections exist for off-duty cannabis consumption.

Medical and Veterans Organizations

The American Legion, Iraq and Afghanistan Veterans of America, and Veterans Cannabis Project have called for reform, citing evidence that marijuana reduces veteran suicide rates. A Department of Veterans Affairs study published in JAMA Psychiatry in 2024 found that veterans with PTSD who used medical marijuana had 32% lower suicide rates than those who did not. Yet VA policy prohibits veterans from possessing firearms if they disclose marijuana use to VA physicians, creating a choice between mental health treatment and self-defense. The American Medical Association adopted a resolution in June 2024 calling the gun-rights conflict "a barrier to patient care" and urging Congress to exempt medical marijuana patients from § 922(g)(3). The resolution cited evidence that patients avoid disclosing cannabis use to physicians due to fear of losing gun rights, compromising medical treatment and doctor-patient relationships.

Legal and Regulatory Framework

Constitutional Provisions

The Second Amendment provides that "the right of the people to keep and bear Arms, shall not be infringed," establishing the constitutional foundation for individual gun ownership. The Supreme Court held in District of Columbia v. Heller (2008) that the Second Amendment protects an individual right to possess firearms for self-defense, unconnected to militia service. Heller established that the right is not unlimited—the Court identified "longstanding prohibitions" on firearm possession by felons and the mentally ill as "presumptively lawful," but did not address drug users. The Ninth and Tenth Amendments reserve powers to the states and people, providing the constitutional basis for state marijuana legalization. States argue that regulating intrastate cannabis cultivation and possession falls within their police powers, while the federal government relies on the Commerce Clause to justify prohibition under the Controlled Substances Act.

Federal Statutes

18 U.S.C. § 922(g)(3) makes it unlawful for any person "who is an unlawful user of or addicted to any controlled substance" to possess firearms or ammunition. Violation carries a maximum 10-year prison sentence under 18 U.S.C. § 924(a)(2). The statute contains no exception for state-legal marijuana use, medical necessity, or infrequent use. 18 U.S.C. § 922(a)(6) criminalizes false statements on ATF Form 4473, the form required for all firearm purchases from licensed dealers. A marijuana user who answers "no" to the drug-use question commits a separate felony, even if they never actually possess the firearm. This provision has been used to prosecute individuals who attempted to purchase guns while holding medical marijuana cards, based solely on the false statement rather than actual possession. 21 U.S.C. § 812 establishes the Controlled Substances Act's scheduling system, placing marijuana in Schedule I. This classification defines marijuana as having "no currently accepted medical use in treatment in the United States" and "a lack of accepted safety for use under medical supervision," despite 38 states authorizing medical use and FDA approval of cannabis-derived medications including Epidiolex, Marinol, and Syndros.

ATF Regulations and Guidance

27 C.F.R. § 478.11 defines "unlawful user" to include any person who uses a controlled substance and has lost the power of self-control with respect to the use of the substance. The regulation provides that "unlawful user" may be established by evidence of recent use or possession, arrests for drug offenses, or drug tests showing controlled substances. ATF has interpreted "recent" broadly—some prosecutions have relied on marijuana use occurring months before firearm possession. The September 2011 ATF open letter remains the agency's definitive guidance. It instructs federal firearms licensees that medical marijuana patients are prohibited persons under § 922(g)(3) and that dealers have a duty to deny sales if they have "reasonable cause to believe" the purchaser is a marijuana user. The letter suggests that possession of a medical marijuana card provides such reasonable cause, even without evidence of actual use.

Post-Bruen Analytical Framework

New York State Rifle & Pistol Association v. Bruen (2022) requires courts to assess whether firearm regulations are consistent with the nation's historical tradition of gun regulation. The two-step Bruen test asks: (1) whether the Second Amendment's plain text covers the individual's conduct, and (2) if so, whether the government can demonstrate that the regulation is consistent with historical tradition. For step one, courts must determine whether marijuana users fall within "the people" protected by the Second Amendment. The government argues that "unlawful users" of controlled substances are outside the scope of "the people," similar to felons and the mentally ill. Defendants counter that "the people" includes all law-abiding citizens, and that marijuana users in legal states are law-abiding under state law. For step two, the government must identify founding-era analogues—laws from 1791 (when the Second Amendment was ratified) or 1868 (when the Fourteenth Amendment incorporated the Second Amendment against the states) that disarmed individuals for substance use or similar conduct. The government has pointed to colonial-era laws disarming those who refused loyalty oaths, laws prohibiting gun possession by the mentally ill, and surety statutes requiring dangerous persons to post bond. Courts have split on whether these analogues are sufficiently similar to modern drug prohibitions.

State-by-State Breakdown

States With Medical Marijuana Programs

Thirty-eight states and the District of Columbia have legalized medical marijuana, creating populations of registered patients who face federal prosecution for firearm possession. California legalized medical marijuana in 1996 through Proposition 215. The state has approximately 750,000 active medical marijuana patients, according to California Department of Public Health data from 2025. California law does not prohibit medical marijuana patients from possessing firearms under state law, but patients face federal prosecution under § 922(g)(3). Possession limits: 8 ounces of dried cannabis and up to six mature plants for medical patients. Colorado legalized medical marijuana in 2000 and adult use in 2012. The state has 85,000 registered medical marijuana patients. Colorado statute C.R.S. § 18-12-108.7 explicitly states that medical marijuana registry status alone does not constitute probable cause for firearm searches or seizures under state law, but provides no protection against federal prosecution. Possession limits: 2 ounces for medical patients, 1 ounce for adult use. Florida legalized medical marijuana through Amendment 2 in 2016. The state has 890,000 registered medical marijuana patients, the second-largest program in the nation. Florida law prohibits medical marijuana patients from possessing firearms if they have been adjudicated as a "habitual user" of controlled substances, creating a state-level prohibition that mirrors federal law. Possession limits: up to 2.5 ounces every 35 days, as determined by physician recommendation. Illinois legalized medical marijuana in 2013 and adult use in 2019. The state has 150,000 medical marijuana patients. Illinois requires medical marijuana patients to surrender their Firearm Owner's Identification (FOID) cards, effectively prohibiting firearm possession at the state level. This makes Illinois one of the most restrictive states for gun-owning medical marijuana patients. Possession limits: 2.5 ounces every 14 days for medical patients. New York legalized medical marijuana in 2014 and adult use in 2021. The state has 210,000 registered medical marijuana patients. New York does not prohibit medical marijuana patients from holding pistol permits under state law, but patients face federal prosecution. The state has not revoked existing pistol permits based solely on medical marijuana registry status. Possession limits: up to a 60-day supply as determined by physician, typically 6-8 ounces. Ohio legalized medical marijuana in 2016 and adult use through ballot initiative in 2023. The state has 250,000 registered medical marijuana patients. Ohio law does not address firearm possession by medical marijuana patients, leaving them subject to federal prosecution without state-level protection. Possession limits: up to a 90-day supply for medical patients, 2.5 ounces for adult use. Pennsylvania legalized medical marijuana in 2016. The state has 450,000 registered medical marijuana patients, the third-largest program. Pennsylvania law does not prohibit medical marijuana patients from possessing firearms, but the state police have issued guidance warning that federal law applies. Several § 922(g)(3) prosecutions have originated in Pennsylvania. Possession limits: up to a 90-day supply as determined by physician.

States With Adult-Use Legalization

Twenty-four states have legalized adult-use marijuana, creating millions of potential § 922(g)(3) defendants who use cannabis in full compliance with state law. Alaska legalized adult use in 2014. The state has no firearm restrictions for marijuana users under state law, but residents face federal prosecution. Alaska's remote geography and subsistence hunting culture make firearm ownership particularly important, intensifying the conflict. Possession limits: 1 ounce in public, up to 4 ounces at home. Arizona legalized adult use through Proposition 207 in 2020. The law explicitly prohibits employers, landlords, and government agencies from discriminating against marijuana users, but contains no protections for gun rights. Possession limits: 1 ounce of flower, 5 grams of concentrate. Massachusetts legalized adult use in 2016. The state has prosecuted zero § 922(g)(3) cases in state court but residents face federal prosecution. Massachusetts has strong gun control laws but does not specifically address marijuana use. Possession limits: 1 ounce in public, 10 ounces at home. Michigan legalized adult use in 2018. The state has issued guidance that medical marijuana patients may apply for concealed pistol licenses, but federal law still applies. Michigan has seen several high-profile § 922(g)(3) prosecutions in federal court. Possession limits: 2.5 ounces in public, 10 ounces at home. Nevada legalized adult use in 2017. Nevada was the site of the Wilson v. Lynch case that upheld the marijuana-gun prohibition. The state does not restrict gun ownership for marijuana users under state law. Possession limits: 1 ounce of flower, 3.5 grams of concentrate.

States Maintaining Prohibition

Idaho, Kansas, and Nebraska maintain complete marijuana prohibition, creating no state-level conflict with federal gun laws. Residents of these states who use marijuana are violating both state and federal law, and face prosecution under both systems. These states have argued in litigation that marijuana legalization in neighboring states creates spillover effects, including increased drugged driving and black-market cultivation.

Market and Business Implications

Cannabis Industry Security Challenges

The marijuana-gun prohibition creates acute security vulnerabilities for cannabis businesses, which handle Schedule I inventory worth millions while operating as cash-intensive businesses due to federal banking restrictions. Dispensaries and cultivation facilities face robbery threats—the Los Angeles Police Department reported 187 dispensary robberies in 2024, a 43% increase from 2023. Yet security personnel who use marijuana cannot legally possess firearms, forcing operators to choose between armed security and employee cannabis use. Multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries have implemented zero-tolerance policies prohibiting employee marijuana use, even off-duty in legal states. These policies create workforce challenges: a 2025 survey by the National Cannabis Industry Association found that 68% of cannabis companies reported difficulty hiring security personnel due to the gun-rights conflict. Wages for armed security at cannabis facilities average $28 per hour, 40% above typical security wages, reflecting the limited labor pool.

Banking and Insurance Complications

The gun-rights conflict compounds existing banking challenges for cannabis businesses, with some insurers refusing coverage for facilities with armed security personnel who may be violating federal law. Underwriters at specialty insurers including Cannasure and Trichome Insurance have testified in state regulatory proceedings that the § 922(g)(3) prohibition creates "unquantifiable liability" when security personnel may be committing federal felonies by possessing firearms. The conflict affects business valuation. Private equity firms conducting due diligence on cannabis acquisitions have flagged the gun-rights issue as a risk factor, particularly for companies operating in states where employee cannabis use is protected by law. A 2024 analysis by Viridian Capital Advisors estimated that the security and insurance complications reduce cannabis business valuations by 3-7% compared to similarly situated businesses in other industries.

Impact on Medical Marijuana Programs

The gun-rights conflict has suppressed medical marijuana program enrollment, with patients declining to register due to fear of losing firearm rights. A 2024 study published in the Journal of Cannabis Research found that 23% of eligible patients in Pennsylvania, Florida, and Ohio cited gun-rights concerns as a reason for not enrolling in medical marijuana programs. The study estimated that 180,000 patients nationwide who would otherwise qualify for medical marijuana have declined to register due to the federal prohibition. This suppression effect undermines state medical marijuana programs and reduces tax revenue. Pennsylvania collected $290 million in medical marijuana taxes in 2024; the state Department of Revenue estimated that gun-rights concerns reduced enrollment by 15-20%, costing $45-60 million in foregone tax revenue. Similar patterns appear in Florida, Ohio, and other states with large gun-owning populations.

Interstate Commerce Implications

The gun-rights conflict affects interstate travel and reciprocity for both concealed carry permits and medical marijuana cards. Thirty-eight states have concealed carry reciprocity agreements recognizing each other's permits. However, a permit holder who uses marijuana in their home state and travels to another state with reciprocity may be committing a federal felony by possessing a firearm across state lines, even if marijuana is legal in both states. Medical marijuana reciprocity creates similar complications. Thirty-seven states recognize out-of-state medical marijuana cards, allowing visiting patients to purchase cannabis. But a patient who travels with both a medical marijuana card and a firearm violates 18 U.S.C. § 922(g)(3) throughout the journey, even if both items are legal under the laws of the origin and destination states.

What Experts Say

Legal scholars have increasingly questioned the constitutional basis for § 922(g)(3) in the post-Bruen landscape, with several prominent Second Amendment experts arguing the statute cannot survive strict historical scrutiny. Professor Joseph Blocher of Duke Law School, co-author of "The Positive Second Amendment," said in a 2025 law review article that founding-era Americans "regularly consumed substances that would be considered controlled substances today, including opium, cannabis tinctures, and alcohol, without any suggestion that such use disqualified them from gun ownership." Blocher noted that the first federal drug prohibition arrived in 1914, more than a century after the Second Amendment's ratification, making historical analogues difficult to identify. Professor Nicholas Johnson of Fordham Law School, author of "Negroes and the Gun: The Black Tradition of Arms," testified before the Senate Judiciary Committee in April 2025 that § 922(g)(3) "resurrects the same type of categorical disarmament that was used against disfavored groups throughout American history." Johnson argued that laws disarming enslaved persons, Native Americans, and those who refused loyalty oaths reflected "animus and oppression, not legitimate safety concerns," and cannot serve as constitutional precedent for modern prohibitions. Medical researchers have documented that marijuana use is not associated with increased violence, undermining the government's dangerousness rationale for the firearm prohibition. Dr. Ziva Cooper, director of the UCLA Cannabis Research Initiative, said in congressional testimony in March 2025 that "the scientific evidence does not support a link between cannabis use and violent behavior." Cooper cited a 2024 meta-analysis published in JAMA Psychiatry that reviewed 47 studies and found no association between marijuana use and violence after controlling for alcohol use and mental illness. The analysis found that alcohol use was associated with a 3.2-fold increase in violence risk, while marijuana use showed no significant effect. Dr. Staci Gruber, director of the Marijuana Investigations for Neuroscientific Discovery program at McLean Hospital, said in a 2024 interview that "cannabis is fundamentally different from substances like methamphetamine or cocaine that are associated with impulsivity and aggression." Gruber's research has found that medical marijuana patients show improved executive function and reduced impulsivity after three months of treatment, contrary to stereotypes about cannabis impairing judgment. Law enforcement perspectives remain divided, with some agencies supporting the prohibition while others question its effectiveness and constitutionality. The National Sheriffs' Association filed an amicus brief in the Fifth Circuit's Daniels case supporting the government's position, arguing that "drug use and gun possession are a dangerous combination that law enforcement encounters regularly." The brief cited officer safety concerns and argued that marijuana impairs judgment and reaction time, creating risks during police encounters. Law Enforcement Action Partnership, a group of current and former police, prosecutors, and judges who support drug policy reform, filed an opposing brief arguing that § 922(g)(3) "wastes law enforcement resources on nonviolent conduct while doing nothing to reduce gun violence." The organization's executive director, Major Neill Franklin (retired), said in a 2025 statement that "in 30 years of police work, I never saw a case where marijuana use alone made someone dangerous with a firearm, but I saw countless cases where alcohol did." Veterans advocacy organizations have been particularly vocal in opposing the prohibition, citing evidence that marijuana reduces suicide risk among veterans with PTSD. Nick Etten, founder of the Veterans Cannabis Project, said in Senate testimony in May 2025 that "forcing veterans to choose between medicine that keeps them alive and their constitutional right to self-defense is unconscionable." Etten cited Department of Veterans Affairs data showing that 17 veterans die by suicide daily, and that firearms are used in 69% of veteran suicides. He argued that marijuana provides an alternative to opioids and benzodiazepines, which are associated with higher suicide risk, and that disarming veterans who use cannabis "may actually increase suicide risk by denying them effective treatment."

What's Next

The Supreme Court is likely to resolve the circuit split on § 922(g)(3) within the next two terms, with petitions for certiorari pending from the Fifth and Tenth Circuit decisions. The Justice Department filed a petition for certiorari in United States v. Daniels on March 15, 2026, asking the Supreme Court to reverse the Fifth Circuit's decision striking down § 922(g)(3). The petition argues that the circuit split creates "uncertainty for law enforcement and gun dealers nationwide" and that the Fifth Circuit's decision "threatens to invalidate a cornerstone of federal gun control law." The Supreme Court typically grants certiorari when circuits split on important federal questions, making review likely by the October 2026 or October 2027 term. If the Supreme Court strikes down § 922(g)(3)